Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma

Cytokine

Volumn 60, Issue 3, 2012, Pages 686-693

  Jang, Jeong Won ^a   Oh, Byong Sun ^a   Kwon, Jung Hyun ^a   You, Chan Ran ^a   Chung, Kyu Won ^a   Kay, Chul Seung ^a   Jung, Hyun Suk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Biological markers; C reactive protein; Hepatocellular carcinoma; Interleukin 6; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; C REACTIVE PROTEIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SURVIVAL TIME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867982366     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.017     Document Type: Article

References (31)

1. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
2. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat Rev Cancer 2003, 3:276-285.
3. Giannitrapani L., Cervello M., Soresi M., Notarbartolo M., La Rosa M., Virruso L., et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci 2002, 963:46-52.
4. Porta C., De Amici M., Quaglini S., Paglino C., Tagliani F., Boncimino A., et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008, 19:353-358.
5. Hsia C.Y., Huo T.I., Chiang S.Y., Lu M.F., Sun C.L., Wu J.C., et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007, 33:208-212.
6. Chau G.Y., Wu C.W., Lui W.Y., Chang T.J., Kao H.L., Wu L.H., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000, 231:552-558.
7. Hattori E., Okumoto K., Adachi T., Takeda T., Ito J., Sugahara K., et al. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unrespectable hepatocellular carcinoma. Hepatol Res 2003, 27:309-314.
8. Hashimoto K., Ikeda Y., Korenaga D., Tanoue K., Hamatake M., Kawasaki K., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864.
9. Nagaoka S., Yoshida T., Akiyoshi J., Akiba J., Torimura T., Adachi H., et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007, 27:1091-1097.
10. Ren Y., Poon R.T., Tsui H.T., Chen W.H., Li Z., Lau C., et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res 2003, 9:5996-6001.
11. Tangkijvanich P., Thong-Ngam D., Mahachai V., Theamboonlers A., Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007, 13:4345-4349.
12. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009, 15:391-423.
13. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
14. Vora S.R., Zheng H., Stadler Z.K., Fuchs C.S., Zhu A.X. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. The Oncologist 2009, 14:717-725.
15. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
16. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
17. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
18. Budhu A., Wang X.W. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006, 80:1197-1213.
19. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
20. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993, 54:1-78.
21. Napoli J., Bishop G.A., McCaughan G.W. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology 1994, 107:789-798.
22. Lee Y., Park U.S., Choi I., Yoon S.K., Park Y.M., Lee Y.I. Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 1998, 4:1711-1717.
23. Reichner J.S., Mulligan J.A., Spisni R., Sotomayor E.A., Albina J.E., Bland K.I. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol 1998, 5:279-286.
24. Kovalovich K., Li W., DeAngelis R., Greenbaum L.E., Ciliberto G., Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem 2001, 276:26605-26613.
25. Soresi M., Giannitrapani L., D'Antona F., Florena A.M., La Spada E., Terranova A., et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006, 12:2563-2568.
26. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
27. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21:159-168.
28. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
29. Wang C.S., Sun C.F. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009, 32:471-482.
30. Nozoe T., Korenaga D., Futatsugi M., Saeki H., Maehara Y., Sugimachi K. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett 2003, 192:89-95.
31. Malaguarnera M., Di Fazio I., Laurino A., Romeo M.A., Giugno I., Trovato B.A. Role of interleukin 6 in hepatocellular carcinoma. Bull Cancer 1996, 83:379-384.